Cubist Pharmaceuticals (CBST) Tests First Patient in Pivotal Global Phase 3 Trial of CXA-201

August 1, 2011 7:51 AM

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of a pivotal Phase 3 trial of CXA-201 in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found